Richards, Merrill & Peterson, Inc. Lantern Pharma Inc. Transaction History
Richards, Merrill & Peterson, Inc.
- $191 Billion
- Q4 2024
A detailed history of Richards, Merrill & Peterson, Inc. transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Richards, Merrill & Peterson, Inc. holds 975 shares of LTRN stock, worth $4,884. This represents 0.0% of its overall portfolio holdings.
Number of Shares
975Holding current value
$4,884% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LTRN
# of Institutions
35Shares Held
2.44MCall Options Held
39.8KPut Options Held
6.1K-
Bios Capital Management, LP Fort Worth, TX1.21MShares$6.05 Million4.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA364KShares$1.82 Million0.0% of portfolio
-
Cm Management, LLC200KShares$1 Million0.6% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny87.3KShares$437,3730.0% of portfolio
-
Geode Capital Management, LLC Boston, MA87KShares$435,7340.0% of portfolio
About Lantern Pharma Inc.
- Ticker LTRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,830,900
- Market Cap $54.3M
- Description
- Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...